LISATA THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $70.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | $-0.59 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | $-0.61 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | $-0.65 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | After market close | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 9, 2023 | After market close | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 6, 2023 | After market close | – | – | – |
Press releases
Announcements Lisata Therapeutics filed with the SEC
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Marea TherapeuticsTransformative cardioendocrine therapies Confidential
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
WAIVER TO AGREEMENT AND PLAN OF MERGER
Other events · EX-99.1 to Form 8-K
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
Material agreement · Other events · EX-99.1 to Form 8-K
Lisata Therapeutics Reports Third Quarter 2025 Financial Results and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata at a Glance Company Overview 3
Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata at a Glance Company Overview 3
Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Lisata at a Glance Company Overview 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Company Overview Lisata at a Glance 3
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Company Overview Lisata at a Glance
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LISATA EUTICSTHERAP Nasdaq-listed clinical stage therapeutics development company with a novel solid tumor targeting and penetration technology to improve the efficacy of anti-cancer drugs 4 Lisata Therapeutics, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LISATA EUTICSTHERAP Nasdaq-listed clinical stage therapeutics development company with a novel solid tumor targeting and penetration technology to improve the efficacy of anti-cancer drugs 4 Lisata Therapeutics, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LISATA EUTICSTHERAP Nasdaq-listed clinical stage therapeutics development company with a novel solid tumor targeting and penetration technology to improve the efficacy of anti-cancer drugs 3 Lisata Therapeutics
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LISATA EUTICSTHERAP Nasdaq-listed clinical stage therapeutics development company with a novel solid tumor targeting and penetration technology to improve the efficacy of anti-cancer drugs 3 Lisata Therapeutics
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
LSTA1 (aka CEND-1) CendR Platform™
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K